Fewer Lucentis injections with new regimen

Article

Preliminary results of a study using the NSAID Xibrom (bromfenac ophthalmic solution 0.09%; ISTA Pharmaceuticals) therapy in combination with Lucentis (ranibizumab; Novartis) in patients with wet age-related macular degeneration (AMD), suggests that it may result in fewer injections being required.

Preliminary results of a study using the NSAID Xibrom (bromfenac ophthalmic solution 0.09%; ISTA Pharmaceuticals) therapy in combination with Lucentis (ranibizumab; Novartis) in patients with wet age-related macular degeneration (AMD), suggests that it may result in fewer injections being required.

The results were obtained from 60 patients receiving Lucentis therapy for wet AMD who were monitored monthly using optical coherence tomography (OCT) and fluorescein angiography. If leakage from vessels was detected, patients were re-injected with Lucentis. Half the subjects received Xibrom twice daily in addition to the Lucentis injections.

Patients who received Lucentis and Xibrom required 1.6±0.69 injections during the six-month study period, whereas those patients receiving just Lucentis required 4.5±0.41 injections. No adverse events were associated with the extended topical administration of Xibrom. Although there was a numerical trend in favour of the combination treatment group on improvement in visual acuity, the difference did not achieve statistical significance.

The full findings will be presented at the ARVO 2008 annual meeting in April.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.